ELP4

ELP4 is a core subunit of the Elp4/5/6 accessory subcomplex of the six-subunit Elongator complex, functioning in tRNA wobble-uridine modification, histone acetylation, and transcription elongation. Within the Elp4/5/6 subcomplex, ELP4 adopts a RecA-ATPase-like fold and assembles into a heterohexameric ring that binds tRNAs in an ATP-regulated manner and is required for the histone acetyltransferase activity of holo-Elongator toward histone H3-K14 and H4-K8 (PMID:22343726, PMID:11904415). Loss of ELP4 disrupts subcomplex integrity and the association of Elp4/5/6 with the Elp1/2/3 catalytic core, abolishing Elongator function (PMID:12424236, PMID:11689709). Patient-derived missense mutations in ELP4 reduce tRNA modification activity and cause a neurodevelopmental disorder distinct from that caused by mutations in Elp1/2/3 subunits, establishing ELP4 as a disease gene with subcomplex-specific neuropathological consequences (PMID:35698786).

1. 2001 High

   ELP4 was identified as part of a discrete Elp4/5/6 subcomplex separable from the Elp1/2/3 core, establishing the modular architecture of Elongator and showing that ELP4 loss phenocopies other elp deletions.

   Evidence TAP purification, affinity chromatography, and genetic disruption in S. cerevisiae

   PMID:11435442 PMID:11689709 PMID:11737649

   Open questions at the time

   • Structural basis for Elp4/5/6 subcomplex assembly unknown
   • No direct biochemical activity assigned to ELP4 itself
   • Mechanism by which Elp4/5/6 supports Elongator function unresolved
2. 2002 High

   ELP4 was shown to be required for Elongator's histone acetyltransferase activity and for structural integrity of the holo-complex, revealing that the accessory subcomplex is not merely structural but essential for catalytic function.

   Evidence In vitro HAT assays on purified Elongator from deletion strains; reciprocal Co-IP mapping subunit dependencies

   PMID:11904415 PMID:12424236

   Open questions at the time

   • Whether ELP4 contacts histones directly or acts allosterically on ELP3 was unknown
   • Whether ELP4 contributes to tRNA modification was not yet addressed
3. 2004 High

   Dissection of subunit-specific roles showed ELP4 is largely dispensable for Elongator's association with nascent RNA transcripts, unlike ELP3, delineating functional asymmetry within the complex.

   Evidence Immunoprecipitation, two-hybrid, and in vivo Elongator-RNA association assays in yeast

   PMID:15138274

   Open questions at the time

   • What substrate ELP4 contributes to recognizing remained unclear
   • Whether ELP4 has ATPase activity was untested
4. 2010 High

   ELP4 knockdown in mouse zygotes impaired paternal genome demethylation, extending Elongator's functional repertoire beyond transcription elongation and tRNA modification to epigenetic reprogramming.

   Evidence siRNA knockdown in mouse zygotes with live-cell methylation imaging, immunostaining, and bisulfite sequencing

   PMID:20054296

   Open questions at the time

   • Whether the demethylation role is direct or a secondary consequence of tRNA modification deficiency
   • Mechanism of Elp3 radical SAM involvement in demethylation not fully resolved
5. 2012 High

   Crystal structures revealed the Elp4/5/6 subcomplex forms a RecA-ATPase-fold heterohexameric ring that binds tRNAs in an ATP-dependent manner and histone H3, providing the first structural framework for how the accessory subcomplex delivers substrates to the catalytic core.

   Evidence Crystal structure determination, in vitro tRNA/histone binding assays, site-directed mutagenesis, ATPase assays

   PMID:22343726 PMID:22556426

   Open questions at the time

   • How tRNA is handed off from Elp4/5/6 ring to Elp3 active site unknown
   • ATP hydrolysis cycle and its coupling to tRNA release not defined
   • Structure of intact holo-Elongator not yet available
6. 2018 Medium

   ELP4 was found to directly interact with the RNA polymerase II CTD, providing biochemical evidence for the long-proposed role of Elongator in transcription elongation beyond tRNA modification.

   Evidence Co-immunoprecipitation of ELP4 with RNAPII CTD in Arabidopsis, ChIP at target loci

   PMID:30401723

   Open questions at the time

   • Interaction demonstrated only in plant system; conservation of ELP4-RNAPII CTD binding in mammals untested
   • Whether this interaction is functionally separable from tRNA modification remains unclear
7. 2022 High

   Patient-derived ELP4 mutations were shown to reduce tRNA modification and cause neurodevelopmental disease distinct from ELP1/2/3 mutations, establishing ELP4 as a human disease gene and revealing functional divergence between the two Elongator subcomplexes for specific tRNA species and cell types.

   Evidence Cryo-EM/crystal structures of human/murine Elp456, in vitro tRNA modification assays, patient cell analyses, mouse modeling

   PMID:35698786

   Open questions at the time

   • Full genotype-phenotype spectrum for ELP4 mutations not yet defined
   • Which specific tRNA species and neuronal populations are most sensitive to ELP4 loss
   • Therapeutic strategies to restore tRNA modification not explored

• How the Elp4/5/6 ring coordinates tRNA substrate selection and handoff to the Elp3 catalytic site within the intact holo-Elongator remains structurally and mechanistically unresolved.
• Full holo-Elongator structure with tRNA substrate bound not yet determined at high resolution
• ATP hydrolysis cycle coupling to tRNA modification catalysis not defined
• Whether ELP4's roles in histone acetylation and tRNA modification are mechanistically separable in vivo